1 week Ago By ABMN Staff
Mizuho began coverage on shares of MannKind ( NASDAQ:MNKD – Free Report ) in a research note released on Thursday morning, Marketbeat reports. The firm issued an outperform rating and a $12.00 target price on the biopharmaceutical company’s stock.
MNKD has been the topic of a number of other research reports. Royal Bank of Canada raised MannKind from a “sector perform” rating to an “outperform” rating and boosted their price target for the stock from $7.00 to $10.
00 in a research report on Thursday, December 19th. Wedbush restated an “outperform” rating and issued a $11.00 price target on shares of MannKind in a research note on Thursday, February 27th.
StockNews.com raised shares of MannKind from a “hold” rating to a “buy” rating in a research report on Wednesday, March 19th. Finally, Wells Fargo & Company assumed coverage on shares of MannKind in a research report on Friday, December 20th.
They issued an “overweight” rating and a $9.00 price objective on the stock. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock.
According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $9.56. View Our Latest Stock Report on MNKD MannKind Stock Up 0.
4 % MannKind ( NASDAQ:MNKD – Get Free Report ) last announced its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported $0.03 EPS for the quarter, meeting analysts’ consensus estimates of $0.
03. The firm had revenue of $76.78 million during the quarter, compared to analysts’ expectations of $74.
99 million. MannKind had a net margin of 8.07% and a negative return on equity of 17.
74%. On average, sell-side analysts expect that MannKind will post 0.1 EPS for the current year.
Hedge Funds Weigh In On MannKind A number of hedge funds have recently bought and sold shares of the business. 180 Wealth Advisors LLC increased its holdings in shares of MannKind by 4.2% during the first quarter.
180 Wealth Advisors LLC now owns 2,194,704 shares of the biopharmaceutical company’s stock worth $11,039,000 after purchasing an additional 88,997 shares during the period. Rhumbline Advisers grew its position in MannKind by 4.4% during the first quarter.
Rhumbline Advisers now owns 399,033 shares of the biopharmaceutical company’s stock worth $2,007,000 after buying an additional 16,807 shares in the last quarter. Mackenzie Financial Corp increased its stake in MannKind by 146.6% during the 4th quarter.
Mackenzie Financial Corp now owns 80,218 shares of the biopharmaceutical company’s stock worth $516,000 after acquiring an additional 47,690 shares during the period. GF Fund Management CO. LTD.
acquired a new position in MannKind in the 4th quarter valued at $37,000. Finally, Focus Partners Advisor Solutions LLC bought a new stake in shares of MannKind during the 4th quarter valued at $111,000. 49.
55% of the stock is owned by institutional investors. About MannKind ( Get Free Report ) MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.
Read More Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter ..
